The research has been recognized with an ASCO Merit Award. Analyzing SEER data, Roswell Park scientists determined that the number of cases of melanoma diagnosed in children, adolescents and young adults increased by 253% from 1973 to 2011. Survival rates also have increased — from 80% for the period 1973-1980 to 95% in 2011. Female young adults appear to be at particular risk for melanoma, a trend that may be due to known risk factors such as high-risk tanning behaviors.
“Given the epidemic rise of melanoma cases diagnosed among children, adolescents and young adults, it is imperative that new research initiatives are implemented, genetic and environmental risk factors identified, and effective prevention and screening strategies employed,” says Demytra Mitsis, MD, lead author of the study and a Fellow in the Department of Medical Oncology at Roswell Park.
The SEER data analysis included 35,726 cases of melanoma identified among individuals less than 40 years of age from 1973 to 2011. Mitsis and colleagues found that 98% of the melanoma cases were diagnosed among adolescents and young adults (aged 15-39 years), and 32 years was the median age. Females comprised 57% of reported cases from 1973 to 1980 and 65.2% of reported cases from 2001 to 2011. The Roswell Park team’s evaluation revealed that the proportion of noninvasive, early-stage melanoma cases increased from 4% of cases for the period 1973 to 1980 to more than 20% of all melanoma cases in 2011.
“The reality is that melanoma is the third most common cancer in those 15 to 39 years old, and these numbers have been steadily increasing. This is a national problem that needs to be addressed, and it begins with awareness and effective prevention strategies,” adds senior author Nikhil Khushalani, MD, Section Chief for Soft Tissue and Melanoma.
The study, “Trends in demographics, incidence, and survival in children, adolescents and young adults (AYA) with melanoma: A Surveillance, Epidemiology and End Results (SEER) population-based analysis,” is abstract number 9058 and will be presented on board no. 301 during the Melanoma/Skin Cancers poster session on Monday, June 1.